Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02035696 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old
A Phase 1 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 1
- Development phase
- 671
- Enrollment target
NCT02035696 is a Phase 1 study that has completed, run by Seqirus. The registered enrollment target is 671 participants.
The verdict
NCT02035696, a Phase 1 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 671 participants
- Enrollment target
Study Summary
To evaluate the safety and immunogenicity of four influenza vaccines in children 6 months to \< 48 months of age
Interventions
- BIOLOGICAL Trivalent influenza vaccine (TIVc)
- BIOLOGICAL Trivalent influenza vaccine-licensed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 671 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02035696
The ClinicalTrials.gov registry entry for NCT02035696 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 671 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seqirus, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Trivalent influenza vaccine (TIVc) is the first listed.
NCT02035696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02035696 about?
NCT02035696 is a clinical study titled "Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old". To evaluate the safety and immunogenicity of four influenza vaccines in children 6 months to \< 48 months of age
What is the current status of trial NCT02035696?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 671 participants. The study started on 2013-12. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02035696?
The interventions under investigation include: Trivalent influenza vaccine (TIVc) (BIOLOGICAL), Trivalent influenza vaccine-licensed (BIOLOGICAL).
Who is sponsoring clinical trial NCT02035696?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.